MOGN Mgi Pharma (MM)

NEW YORK, Jan. 23 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on Monday January 28, 2008 Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) will replace MGI Pharma, Inc. (NASDAQ:MOGN) in the HealthShares(TM) Composite Index. MGI Pharma is being acquired by Eisai Pharma of Japan (Tokyo, TSE:4523). Eisai Pharma will replace MGI Pharma in the HealthShares(TM) Cancer Index, and Dr. Reddy's Laboratories, Ltd (NYSE:RDY) will replace MGI Pharma in the HealthShares(TM) Neuroscience Index. The Composite Index consists of the 80 largest companies by market capitalization that are engaged in healthcare, life sciences and/or biotechnology that are part of the 20 Composite eligible Indexes. Companies included in the HealthShares(TM) Cancer Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of cancers. They generally include those with substantial revenues and significant research and development programs. Companies included in the HealthShares(TM) Neuroscience Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of neurological and psychiatric disorders including, but not limited to, Alzheimer's, Parkinson's, Huntington's, schizophrenia, anxiety, depression, epilepsy, pain and sleep disorders. The weightings for Regeneron Pharmaceuticals in the HealthShares(TM) Composite Index, Eisai Pharma in the HealthShares(TM) Cancer Index and Dr. Reddy's Laboratories, Ltd. in the HealthShares(TM) Neuroscience Index will be identical to those of companies being removed from their indexes on the effective date. About QED International Associates QEDI International, based in New York, is a leading financial industry consulting firm specializing in quantitative modeling and the design, development and maintenance of indexes and Exchange Traded Funds. For more information, visit the company's website at http://www.qedinternational.com/ DATASOURCE: QED International Associates, Inc. CONTACT: Ed Matluck, CEO, or Michael Carty, Senior Advisor, both for QED International, +1-212-953-4058 Web site: http://www.qedinternational.com/

Copyright